Yeah.

But I think it is starting to have a huge negative impact, and I think in the next 10 years, we're going to see it probably breaking the National Health Service, the NHS.

At the moment, access through the healthcare system, through your primary care provider, through your GP, is very limited, um, because of the costs.

But, uh, the organization in the UK who okays drugs for funding through the health service, uh, approved both Ozempic and, um, Mounjaro full use in the UK on the basis of evidence of people with severe, very heavy financial interests in this narrative, some of which were not declared, and on scientific evidence that if they had dug a little bit closer, wouldn't have actually supported the moves they were making.

So, for example, um, it was approved for people with a BMI over 35, um, despite the fact that the so-called longer term trials, which means like two years, uh, were showing that it-- they don't actually work terribly well for cardiovascular health.In that group of people.

They don't actually improve health for, based on the data we have so far, in a large study it was shown that overall there were some improvements in cardiovascular health, but not for people with higher BMI, older people, women, people of color.

And people are not looking at this evidence, and most of this evidence is actually buried in supplementary materials to journal articles.

And what is-- what do you see it playing a role in the work we're doing here?